- Home
- MNPR vs GCO Comparison
MNPR vs GCO Comparison
Compare MNPR & GCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | GCO |
|---|---|---|
| Founded | 2014 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.9M | 432.0M |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MNPR | GCO |
|---|---|---|
| Price | $59.35 | $42.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $107.00 | $33.00 |
| AVG Volume (30 Days) | 149.2K | ★ 174.8K |
| Earning Date | 05-08-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.99 | ★ 171.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,606,898,000.00 |
| Revenue This Year | N/A | $0.78 |
| Revenue Next Year | N/A | $2.12 |
| P/E Ratio | ★ N/A | $34.18 |
| Revenue Growth | N/A | ★ 13.71 |
| 52 Week Low | $29.18 | $19.62 |
| 52 Week High | $105.00 | $42.72 |
Technical Indicators
Market Signals| Indicator | MNPR | GCO |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 68.93 |
| Support Level | $56.02 | $30.06 |
| Resistance Level | $60.67 | N/A |
| Average True Range (ATR) | 3.50 | 2.29 |
| MACD | -0.56 | 0.41 |
| Stochastic Oscillator | 15.69 | 90.62 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About GCO Genesco Inc.
Genesco Inc sells footwear, headwear, sports apparel, and accessories. It has four reportable business segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass. The brands of the company are: Journeys; Journeys Kidz; Little Burgundy; Schuh; Johnston & Murphy; and Genesco Brands Group.